Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: POLL
Liczba odnalezionych rekordów: 2



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/2

Tytuł oryginału: Modulation of pulmonary innate immunity during bacterial infection - animal studies.
Autorzy: Schultz Marcus J., Poll Tom van der
Źródło: Arch. Immunol. Ther. Exp. 2002: 50 (3) s.159-167, il., tab., bibliogr. 68 poz.
Sygnatura GBL: 304,223

Hasła klasyfikacyjne GBL:
  • mikrobiologia
  • pulmonologia

    Typ dokumentu:
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • zwierzęta

    Streszczenie angielskie: Both the increasing number of immunocompromised patients susceptible to pneumonia and the development of bacterial resistance are sgnificant problems related to the treatment of pneumonia. The primary outcome of treatment for pneumonia is to tip tha balance a successful host response. An ideal approach would be a combination of immunomodulayion and conventional antimicrobial therapy. It is of increasing imoprtance to understand the components of innate immunity, before immunomodulatory therapy can be applied to patients. Much of our knowledge of the role of alveolar macrophages, cytokines and chemokines in the pathogenesis of pneumonia is derived from animal studies on experimental pneumonia. This article summarizes current information on the role of an alveolar macrophage (AM) and AM-derived mediators in host defense against pneumonia.

    2/2

    Tytuł oryginału: Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
    Autorzy: Camirand Anne, Lu Yuhong, Pollak Michael
    Źródło: Med. Sci. Monitor 2002: 8 (12) s.BR521-BR526, il., bibliogr. 32 poz.
    Sygnatura GBL: 313,278

    Hasła klasyfikacyjne GBL:
  • onkologia

    Typ dokumentu:
  • praca doświadczalna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • in vitro

    Streszczenie angielskie: Background: The humanized anti-HER2 monoclonal antibody trastuzamab (Herceptin) is useful in the treatment of ErbB2-overexpressing breast cancers, but its efficiency is limited because development of resistance is common. In order to study the possibility of improving the efficacy of therapies directed against HER2/erbB2, we investigated the effects of co-targeting this receptor and the insulin-like growth factor 1 receptor (IGF-1R), a widely-expressed protein tyrosine kinase with important roles in suppression of apoptosis and stimulation of proliferation. Material/methods: The experimental strategy involved combining trastuzumab treatment and reduction of IGF-1R signaling through incremental heat-induced expression of the dominant-negative IGF-1 receptor 486/STOP under the control of the heat-sensitive Drosophila HSP70 promoter, in HER2/erbB2-overexpressing MCF7her 18 breast cancer cells. Results: Isobologram analysis of combinatorial treatment data revealed a strong synergistic interaction between trastuzumab treatment and the indication of the dominant-negative IGF-1R expression, resulting in potentiation of growth inhibition in transfected cancer cells. Conclusions: These observations support the concept that simultaneously co-targeting tyrosine kinase receptors may be therapeutically useful, and provide a specific rationale for combining IGF-1R and HER2/erbB2 targeting strategies in anti-neoplastic approaches.

    stosując format: